Back to ISIS Stock Lookup

ISIS – Analyst Comments

Mar 31, 2014 11:32 AM ISIS Pharmaceuticals (ISIS) ApoCIII Continues to Show Unprecedented Lipid Benefits - BMO Capital
Mar 27, 2014 06:45 AM Activity of ISIS 560131/AZD5321 (ISIS) 'Incredibly Exciting' - BMO Capital
Mar 24, 2014 01:13 PM Arrowhead Research (ARWR): HBV Market Large Enough for Many Developers, says Deutsche Bank (ISIS)
Mar 10, 2014 02:52 PM Competitor Data Positive for ISIS Pharmaceuticals (ISIS), BMO Capital Says
Feb 24, 2014 11:07 AM Tekmira Pharma (TKMR) Jumps as Maxim Group Nearly Doubles Price Target
Feb 21, 2014 11:24 AM Needham & Company Ratchets Price Target on ISIS Pharmaceuticals (ISIS) to $61 on Positive Data
Feb 21, 2014 10:44 AM ISIS (ISIS) Data Encouraging; Infants Coming Soon, Says Deutsche Bank
Jan 22, 2014 06:43 AM Deutsche Bank Starts ISIS Pharmaceuticals (ISIS) at Buy
Sep 23, 2013 02:13 PM ISIS Pharmaceuticals (ISIS) PT Raised to $46 at Needham & Company on Positive Data
Sep 4, 2013 07:24 AM Goldman Sachs Starts ISIS Pharmaceuticals (ISIS) at Neutral; Sees 30% Downside if SMN-Rx Fails
Jul 22, 2013 08:17 AM Needham & Company Lifts PT on ISIS Pharmaceuticals (ISIS)
Jun 24, 2013 11:40 AM Needham & Company Boosts ISIS Pharmaceuticals (ISIS) PT to $29
Jun 24, 2013 10:56 AM ISIS Pharmaceuticals (ISIS) Results Called 'Stunning'
Jun 4, 2013 07:58 AM Needham & Company Upbeat on ISIS Pharmaceuticals (ISIS) Following ASCO
Mar 21, 2013 01:21 PM Analyst Cautiously Optimistic on ISIS (ISIS) SMN (Rx)
Oct 23, 2012 03:59 PM Isis Pharmaceuticals (ISIS) on Traders Radars Ahead of Cramer Mad Money Interview
Oct 19, 2012 01:43 PM Needham Reiterates Buy on ISIS (ISIS) Following Narrow FDA Vote for Approval of Kynamro
Oct 19, 2012 08:47 AM Jefferies Cuts Numbers on ISIS Pharmaceuticals (ISIS) Despite Panel Backing
Aug 7, 2012 09:52 AM Canaccord Genuity Maintains Hold and Raises Price Target on ISIS Pharmaceuticals (ISIS)
May 9, 2012 09:55 AM Correction - Canaccord Genuity maintains a 'Hold' on ISIS Pharmaceuticals (ISIS)
May 9, 2012 09:52 AM Canaccord Genuity Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); Adjusting Estimates After Top & Bottom Line Beat
Nov 8, 2011 01:48 PM Jefferies Cuts Price Targets on ISIS Pharmaceuticals (ISIS), Has Enough Cash Through 2014
Aug 8, 2011 08:27 AM Needham & Company Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); 2Q11/Early 3Q11 Review - Mipomersen Application in EU (Submitted) and US (Expected by YE11)
Apr 14, 2011 07:52 AM Needham & Company Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); Pipeline Progress Review – Long-Term, Early Stage Programs Are Encouraging
Mar 1, 2011 01:44 PM Barclays Maintains an 'Overweight' on ISIS Pharmaceuticals (ISIS); 4Q10 Update - Mipomersen Filings on Track
Mar 1, 2011 10:31 AM Needham & Company Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); Strong Focus on Mipomersen Next Steps by Genzyme, Steady Progress of Early-Stage Pipeline
Feb 17, 2011 10:34 AM Canaccord Genuity Morning Coffee on Sanofi-Aventis (SNY) and Genzyme (GENZ): An Extra $5 Will Help The Medicine Go Down
Jan 11, 2011 07:49 AM Needham & Company Reiterates a 'Hold' on ISIS Pharmaceuticals (ISIS); FDA Views Mipomersen Data as Sufficient to Submit HoFH NDA
Jul 27, 2010 09:37 AM Morgan Joseph Adds Onyx Pharma (ONXX) to 'Trading List' Following Positive Data on Carfilzomib
Jun 18, 2010 07:56 AM Needham & Company Reiterates a 'Buy' on ISIS Pharmaceuticals (ISIS), Well Positioned to Address Genetic Disorders
Jun 3, 2010 07:38 AM Needham & Company Reiterates a 'Buy' on ISIS Pharmaceuticals (ISIS); Annual Meeting Highlighted
May 28, 2010 01:08 PM Citi 2010 Healthcare Conference Key Takeaways - MRK, PFE, BMY, ISIS, NPSP, & MYGN
May 20, 2010 07:56 AM Needham & Company Reiterates a 'Buy' on ISIS Pharmaceuticals (ISIS); Pipelines to Address Cancer Through Antisense Technology
Apr 15, 2010 07:56 AM Needham & Company reiterates a 'Buy' on ISIS Pharmaceuticals (ISIS); Cardiovascular Program Update – Multiple Well-Characterized Drug Candidates
Feb 11, 2010 09:40 AM Analysts Thoughts On Isis Pharmaceuticals (ISIS) After 19% Sell-Off
Nov 18, 2009 08:16 AM Morgan Joseph Reiterates a 'Buy' on Isis Pharmaceuticals (ISIS); Could Be Acquired by Potential Partners
Nov 18, 2009 07:30 AM Piper Jaffray Maintains an 'Overweight' on ISIS Pharmaceuticals (ISIS); Price Target Cut
May 27, 2008 08:42 AM BWS Financial Comments Positively on Isis Pharmaceuticals (ISIS); Maintains Buy
Apr 25, 2008 12:22 PM Piper Jaffray Tells Clients To Buy ISIS Pharma (ISIS) On Today's Weakness
Jan 31, 2008 10:32 AM Piper Jaffray raises its price target on ISIS Pharmaceuticals (ISIS) to $29
Jan 17, 2008 09:11 AM ISIS Pharma (ISIS): Actionable Trading Call from Jefferies
Jan 14, 2008 10:20 AM BWS Financial Says ISIS Pharma (ISIS) Could Goto $30
Jan 8, 2008 08:58 AM Analyst Firms Raise Price Targets on ISIS Pharmaceuticals (ISIS)
Jan 8, 2008 08:35 AM Needham Raises Price Target On Isis Pharma (ISIS) To $26
Sep 13, 2007 12:52 PM Piper Jaffray Raises its price target on ISIS Pharmaceuticals (ISIS) to $17
Jul 9, 2007 10:40 AM Piper Jaffray Said ISIS Pharma (ISIS) To Get Royalty Payments from Alnylam/Roche deal
Oct 31, 2006 09:03 AM Needham Comments on Other Stocks in RNAi Following Merck's Deal to Buy Sirna Therapeutics
May 10, 2006 09:38 AM Needham Raises its Price Target on ISIS
Dec 22, 2005 10:17 AM Analyst Note Revisited After AGIX/AZN Deal
Jun 17, 2005 12:43 PM Needham Biotech Analyst Highlights Late Stage Drugs Without Partners

Back to ISIS Stock Lookup